PROTARA THERAPEUTIC INC
TARANASDAQTrading Snapshot
- Day Range
- $3.85 – $3.93
- 52-Week Range
- $2.97 – $7.82
- Volume
- $2.46B
- Avg Volume
- $1.77B
- Shares Outstanding
- 56.2M
- Next Earnings
- Sep 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $17M
- Last Q Revenue
- $180,000
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.35
- Dividend Yield
- —
Why Investors Own TARA
- ✓High-growth profile — revenue up +34.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About PROTARA THERAPEUTIC INC
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Protara Therapeutics Q2 EPS $(0.36) Misses $(0.33) Estimate
Protara Therapeutics (NASDAQ:TARA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 2.86 percent decrease over losses of $(0.35) per share
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
Protara Therapeutics (TARA) buy thesis: $9.96 fair value vs ~$4, upside from TARA-002 & IV choline chloride, cash runway to 2028. Read here for more.